The Cause-and-Effect Relationship Between Type 2 Diabetes Mellitus and Clinically Overt Cryptogenic Cirrhosis: A Matter That Must Be Seriously Revised

authors:

avatar Abbas Tavakolian Arjmand 1 , * , avatar Nasrin Razavianzadeh 1

Internal Medicine Department, Shahrood Medical School, Islamic Azad University, Semnan, IR Iran

how to cite: Tavakolian Arjmand A, Razavianzadeh N. The Cause-and-Effect Relationship Between Type 2 Diabetes Mellitus and Clinically Overt Cryptogenic Cirrhosis: A Matter That Must Be Seriously Revised. Hepat Mon. 2016;16(9):e36485. https://doi.org/10.5812/hepatmon.36485.

Acknowledgements

References

  • 1.

    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8. [PubMed ID: 7382552].

  • 2.

    Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29(3):664-9. [PubMed ID: 10051466]. https://doi.org/10.1002/hep.510290347.

  • 3.

    Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22 Suppl 2:24-7. [PubMed ID: 16225467]. https://doi.org/10.1111/j.1365-2036.2005.02590.x.

  • 4.

    Balkau B, Eschwege E, Ducimetiere P, Richard JL, Warnet JM. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol. 1991;44(6):465-74. [PubMed ID: 2037851].

  • 5.

    Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med. 2005;22(8):973-9. [PubMed ID: 16026360]. https://doi.org/10.1111/j.1464-5491.2005.01595.x.

  • 6.

    Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25(5):815-21. [PubMed ID: 11978674].

  • 7.

    de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22(5):756-61. [PubMed ID: 10332677].

  • 8.

    Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734-43. [PubMed ID: 17327353]. https://doi.org/10.2337/dc06-1539.

  • 9.

    Silverman JF, O'Brien KF, Long S, Leggett N, Khazanie PG, Pories WJ, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990;85(10):1349-55. [PubMed ID: 2220728].

  • 10.

    Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2(3):262-5. [PubMed ID: 15017611].

  • 11.

    Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2009;16(2):141-9. [PubMed ID: 19262374]. https://doi.org/10.1097/MED.0b013e3283293015.

  • 12.

    Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32(4 Pt 1):689-92. [PubMed ID: 11003611]. https://doi.org/10.1053/jhep.2000.17894.

  • 13.

    Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30(11):2940-4. [PubMed ID: 17666460]. https://doi.org/10.2337/dc07-0792.

  • 14.

    Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL, et al. Does this patient with liver disease have cirrhosis? JAMA. 2012;307(8):832-42. [PubMed ID: 22357834]. https://doi.org/10.1001/jama.2012.186.

  • 15.

    Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1997;92(8):1302-4. [PubMed ID: 9260794].

  • 16.

    El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol. 2001;96(8):2462-7. [PubMed ID: 11513191]. https://doi.org/10.1111/j.1572-0241.2001.04054.x.